<?xml version='1.0' encoding='utf-8'?>
<document id="31872743"><sentence text="[Prediction of potential drug interactions of apigenin based on molecular docking and in vitro inhibition experiments]."><entity charOffset="46-54" id="DDI-PubMed.31872743.s1.e0" text="apigenin" /></sentence><sentence text="The purpose of this study was to investigate the effect of apigenin on UGT1 A1 enzyme activity and to predict the potential drug-drug interaction of apigenin in clinical use"><entity charOffset="59-67" id="DDI-PubMed.31872743.s2.e0" text="apigenin" /><entity charOffset="149-157" id="DDI-PubMed.31872743.s2.e1" text="apigenin" /><pair ddi="false" e1="DDI-PubMed.31872743.s2.e0" e2="DDI-PubMed.31872743.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31872743.s2.e0" e2="DDI-PubMed.31872743.s2.e1" /></sentence><sentence text=" First,on the basis of previous experiments,the binding targets and binding strength of apigenin to UGT1 A1 enzyme were predicted by computer molecular docking method"><entity charOffset="88-96" id="DDI-PubMed.31872743.s3.e0" text="apigenin" /></sentence><sentence text=" Then the inhibitory effect of apigenin on UGT1 A1 enzyme was evaluated by in vitro human liver microsomal incubation system"><entity charOffset="31-39" id="DDI-PubMed.31872743.s4.e0" text="apigenin" /></sentence><sentence text=" Molecular docking results showed that apigenin was docked into the active region of UGT1 A1 enzyme protein F,consistent with the active region of bilirubin docking,with moderate affinity"><entity charOffset="39-47" id="DDI-PubMed.31872743.s5.e0" text="apigenin" /><entity charOffset="147-156" id="DDI-PubMed.31872743.s5.e1" text="bilirubin" /><pair ddi="false" e1="DDI-PubMed.31872743.s5.e0" e2="DDI-PubMed.31872743.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31872743.s5.e0" e2="DDI-PubMed.31872743.s5.e1" /></sentence><sentence text=" Apigenin flavone mother nucleus mainly interacted with amino acid residues ILE343 and VAL345 to form hydrophobic binding Pi-Alkyl"><entity charOffset="1-17" id="DDI-PubMed.31872743.s6.e0" text="Apigenin flavone" /><entity charOffset="56-66" id="DDI-PubMed.31872743.s6.e1" text="amino acid" /><entity charOffset="122-130" id="DDI-PubMed.31872743.s6.e2" text="Pi-Alkyl" /><pair ddi="false" e1="DDI-PubMed.31872743.s6.e0" e2="DDI-PubMed.31872743.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31872743.s6.e0" e2="DDI-PubMed.31872743.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31872743.s6.e0" e2="DDI-PubMed.31872743.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31872743.s6.e1" e2="DDI-PubMed.31872743.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31872743.s6.e1" e2="DDI-PubMed.31872743.s6.e2" /></sentence><sentence text=" At the same time,the hydroxyl group on the mother nucleus and the amino acid residue LYS346 formed an additional hydrogen bond,which increased the binding of the molecule to the protein"><entity charOffset="22-30" id="DDI-PubMed.31872743.s7.e0" text="hydroxyl" /><entity charOffset="67-77" id="DDI-PubMed.31872743.s7.e1" text="amino acid" /><entity charOffset="86-92" id="DDI-PubMed.31872743.s7.e2" text="LYS346" /><entity charOffset="114-122" id="DDI-PubMed.31872743.s7.e3" text="hydrogen" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e0" e2="DDI-PubMed.31872743.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e0" e2="DDI-PubMed.31872743.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e0" e2="DDI-PubMed.31872743.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e0" e2="DDI-PubMed.31872743.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e1" e2="DDI-PubMed.31872743.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e1" e2="DDI-PubMed.31872743.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e1" e2="DDI-PubMed.31872743.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e2" e2="DDI-PubMed.31872743.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31872743.s7.e2" e2="DDI-PubMed.31872743.s7.e3" /></sentence><sentence text=" These results suggested that the flavonoid mother nucleus structure had a special structure binding to the enzyme protein UGT1 A1,and the introduction of hydroxyl groups into the mother nucleus can increase the binding ability"><entity charOffset="34-43" id="DDI-PubMed.31872743.s8.e0" text="flavonoid" /><entity charOffset="155-163" id="DDI-PubMed.31872743.s8.e1" text="hydroxyl" /><pair ddi="false" e1="DDI-PubMed.31872743.s8.e0" e2="DDI-PubMed.31872743.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31872743.s8.e0" e2="DDI-PubMed.31872743.s8.e1" /></sentence><sentence text=" In vitro inhibition experiments showed that apigenin had a moderate inhibitory effect on UGT1 A1 enzyme in a way of competitive inhibition,which was consistent with the results of molecular docking"><entity charOffset="45-53" id="DDI-PubMed.31872743.s9.e0" text="apigenin" /></sentence><sentence text=" The results of two experiments showed that apigenin was the substrate of UGT1 A1 enzyme,which could inhibit the activity of UGT1 A1 enzyme competitively,and there was a risk of drug interaction between apigenin and UGT1 A1 enzyme substrate in clinical use"><entity charOffset="44-52" id="DDI-PubMed.31872743.s10.e0" text="apigenin" /><entity charOffset="203-211" id="DDI-PubMed.31872743.s10.e1" text="apigenin" /><pair ddi="false" e1="DDI-PubMed.31872743.s10.e0" e2="DDI-PubMed.31872743.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31872743.s10.e0" e2="DDI-PubMed.31872743.s10.e1" /></sentence><sentence text="" /></document>